Stock Events

Stock Events

Immunic 

0
123
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q4 2025
Q1 2026
Next
-1.03
-0.88
-0.73
-0.59
Expected EPS
-1.0291757668800001
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-84.54MNet Income

Analyst Ratings

11.10Average Price Target
The highest estimate is 20.49.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 10V.STU. It's not an investment recommendation.
NVIDIA
16
NVDA
Amazon
13
AMZN
Microsoft
12
MSFT
AMD
12
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on discovering, developing, and delivering therapies for neurological diseases, similar to Immunic's focus on immune-mediated diseases.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is involved in the research and development of therapeutic treatments for a variety of diseases, including those in Immunic's target areas.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie operates in the same biopharmaceutical field, focusing on immunology and chronic diseases, competing directly with Immunic's product pipeline.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics, including treatments for illnesses in areas that overlap with Immunic's research, such as inflammatory diseases.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb, having acquired Celgene, continues to be a competitor with a strong portfolio in immunology and oncology, areas relevant to Immunic.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals specializes in developing medications for autoimmune diseases and inflammatory conditions, directly competing with Immunic's therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals engages in creating new therapies for treating cystic fibrosis and other serious diseases, competing for similar patient populations as Immunic.
Novartis
NVS
Mkt Cap293.94B
Novartis is a global healthcare company that has a broad range of products competing across several of Immunic's key areas, including immunology.
Pfizer
PFE
Mkt Cap137.76B
Pfizer operates globally in various therapeutic areas, including inflammation and immunology, making it a competitor to Immunic in the biopharmaceutical sector.

About

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Show more...
CEO
ISIN
US4525EP2001

Listings

F
DE
10V.F
MU
DE
10V.MU
STU
DE
10V.STU
XNAS
US
IMUX

0 Comments

Share your thoughts

FAQ

What is Immunic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Immunic stocks are traded under the ticker 10V.STU.
When is the next Immunic earnings date?▼
Immunic is going to release the next earnings report on August 06, 2026.
What were Immunic earnings last quarter?▼
10V.STU earnings for the last quarter are -0.92 EUR per share, whereas the estimation was -0.59 EUR resulting in a -57.09% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Immunic revenue for the last year?▼
Immunic revenue for the last year amounts to 0 EUR.
What is Immunic net income for the last year?▼
10V.STU net income for the last year is -84.54M EUR.
In which sector is Immunic located?▼
Immunic operates in the Other sector.
When did Immunic complete a stock split?▼
The last stock split for Immunic was on April 27, 2026 with a ratio of 1:10.